Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.

Ferguson, Gary T; Feldman, Gregory; Pudi, Krishna K; Barnes, Chris N; Moran, Edmund J; Haumann, Brett; Pendyala, Srikanth; Crater, Glenn

Ferguson, Gary T; Feldman, Gregory; Pudi, Krishna K; Barnes, Chris N; Moran, Edmund J; Haumann, Brett; Pendyala, Srikanth; Crater, Glenn.

Afiliação

Ferguson GT; Pulmonary Research Institute of Southeast Michigan, Farmington Hills.
Feldman G; South Carolina Pharmaceutical Research, Spartanburg.
Pudi KK; Sherman Clinical Research, Sherman, Texas.
Barnes CN; Theravance Biopharma US, Inc., South San Francisco, California.
Moran EJ; Theravance Biopharma US, Inc., South San Francisco, California.
Haumann B; Theravance Biopharma US, Inc., South San Francisco, California.
Pendyala S; Theravance Biopharma US, Inc., South San Francisco, California.
Crater G; Theravance Biopharma US, Inc., South San Francisco, California.

Chronic Obstr Pulm Dis ; 6(2): 154-165, 2019 Apr 09.

Article em En | MEDLINE | ID: mdl-30974049

Palavras-chave

FEV1; Phase III randomized controlled trial; Revefenacin; chronic obstructive pulmonary disease; copd; forced expiratory volume in 1 second; nebulized therapy,Phase III randomized controlled trial

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Chronic Obstr Pulm Dis Ano de publicação: 2019 Tipo de documento: Article